DDN is a selective Insulin Receptor activator and insulin sensitizer that mimics insulin activity with oral efficacy. It can directly bind to the receptor kinase domain, inducing Akt and ERK phosphorylation, and enhances insulin-stimulated glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice.